• Andrea Frilling, Georgios C Sotiropoulos, Jun Li, Oskar Kornasiewicz, and Ursula Plöckinger.
• Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. a.frilling@imperial.ac.uk
• HPB (Oxford). 2010 Aug 1; 12 (6): 361-79.

BackgroundThe incidence of neuroendocrine tumours (NET) has increased over the past three decades. Hepatic metastases which occur in up to 75% of NET patients significantly worsen their prognosis. New imaging techniques with increasing sensitivity enabling tumour detection at an early stage have been developed. The treatment encompasses a panel of surgical and non-surgical modalities.MethodsThis article reviews the published literature related to management of hepatic neuroendocrine metastases.ResultsAbdominal computer tomography, magnetic resonance tomography and somatostatin receptor scintigraphy are widely accepted imaging modalities. Hepatic resection is the only potentially curative treatment. Liver transplantation is justified in highly selected patients. Liver-directed interventional techniques and locally ablative measures offer effective palliation. Promising novel therapeutic options offering targeted approaches are under evaluation.ConclusionsThe treatment of neuroendocrine liver metastases still needs to be standardized. Management in centres of expertise should be strongly encouraged in order to enable a multidisciplinary approach and personalized treatment. Development of molecular prognostic factors to select treatment according to patient risk should be attempted.

26 keywords...

hide…